CRISPR Therapeutics outlook: scaling gene editing by 2036. Key takeaways. * CRISPR Therapeutics currently reports $10.2 million in quarterly revenue against a $91.2 million net loss, highlighting the heavy R&D burden of its current pipeline. * The company is pivoting from ex-vivo therapies like Casgevy toward in-vivo editing, which could expand its addressable patient population from 150,000 to 400,000. * By 2036, the success of SyNTase editing and in-vivo delivery methods will determine if the firm transitions from a niche biotech to a diversified genomic medicine powerhouse. TrendPulse analysis. Industry context. The gene-editing landscape is moving beyond the "proof of concept" phase into a period of rigorous commercial validation. Historically, the sector has been defined by high-cost, one-time curative treatments. However, the industry is now facing a "delivery bottleneck." Competitors like **Intellia Therapeutics** and **Beam Therapeutics** are also racing to solve the in-vivo delivery challenge, as the market increasingly favors standardized, off-the-shelf products over the bespoke, patient-specific manufacturing processes that currently dominate the space. Furthermore, the regulatory environment is becoming more sophisticated. As seen with recent setbacks at major pharmaceutical firms like **Novartis**, regulators are no longer satisfied with biomarker improvements alone. They now demand clear, long-term clinical outcomes that translate into tangible patient health benefits. This shift forces companies like CRISPR Therapeutics to prove not just that they can edit a gene, but that the edit reliably prevents disease progression in real-world settings. The industry is effectively moving from a "technology-first" mindset to a "clinical-outcome-first" mandate. Why this matters. For investors and industry stakeholders, the next decade represents a transition from speculative growth to operational maturity. The primary risk is no longer just scientific failure, but commercial viability. If CRISPR Therapeutics successfully transitions to in-vivo delivery, it will fundamentally change the economics of the business, moving from a high-cost service model to a scalable product model. This would likely trigger a wave of M&A activity, as large-cap pharmaceutical companies look to acquire proven, scalable genomic platforms to replenish their aging pipelines. However, the path to 2036 is fraught with "clinical disconnect" risks - where the editing works, but the patient outcome does not improve as expected. Decision-makers should monitor the company's ability to manage its cash burn while navigating these long-term trials. The winners in this space will be those who can balance the high costs of R&D with a clear, cost-effective path to commercialization. Investors should look for evidence of manufacturing efficiency and partnerships that can handle the global distribution of these complex therapies once they reach the market. The bottom line. CRISPR Therapeutics' long-term value hinges on its ability to transition from complex, ex-vivo procedures to scalable in-vivo therapies that deliver measurable, long-term clinical outcomes. Read the full article. This analysis is based on reporting from nasdaq Finance AI-powered news analysis · September 18, 2026 Editorially Reviewed

Intellia Therapeutics' (NTLA) market outperform rating reiterated at Citizens Jmp. September 9, 2026 Key points. * Citizens JMP reiterated its "Market Outperform" rating on Intellia Therapeutics and maintained a $30 price target, implying approximately 135% upside from the reported $12.74 share price. * Analyst sentiment remains mixed: Intellia has an average rating of "Hold" and an average price target of $20.98, despite recent "Outperform" and "Buy" upgrades or reiterations from several firms. * Intellia reported a quarterly loss of $0.80 per share, in line with estimates, but revenue of $7.66 million fell short of the $12.98 million consensus and declined 46.4% year over year. * MarketBeat previews top five stocks to own in October. Intellia Therapeutics (NASDAQ:NTLA - Get Free Report)'s stock had its "market outperform" rating reissued by investment analysts at Citizens Jmp in a report issued on Wednesday, Benzinga reports. They presently have a $30.00 price objective on the stock. Citizens Jmp's price target points to a potential upside of 135.48% from the stock's current price. NTLA has been the topic of several other research reports. Evercore raised Intellia Therapeutics from a "hold" rating to an "outperform" rating and set a $24.00 price objective on the stock in a research note on Friday, August 7th. HC Wainwright restated a "buy" rating and issued a $25.00 price objective on shares of Intellia Therapeutics in a report on Wednesday. Sanford C. Bernstein increased their target price on shares of Intellia Therapeutics from $13.00 to $17.00 and gave the stock a "market perform" rating in a report on Wednesday, May 13th. Wedbush lifted their price objective on shares of Intellia Therapeutics from $12.00 to $13.00 and gave the company a "neutral" rating in a report on Wednesday. Finally, Citigroup restated a "market outperform" rating on shares of Intellia Therapeutics in a report on Tuesday, August 25th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, eight have assigned a Hold rating and four have given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $20.98. Intellia Therapeutics stock performance. NASDAQ:NTLA opened at $12.74 on Wednesday. The stock has a fifty day simple moving average of $12.78 and a 200-day simple moving average of $13.42. The company has a market cap of $1.79 billion, a price-to-earnings ratio of -3.79 and a beta of 1.82. Intellia Therapeutics has a twelve month low of $7.95 and a twelve month high of $28.25. Discover more Get Business Reports Cryptocurrency market data Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.80) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.80). The company had revenue of $7.66 million during the quarter, compared to analyst estimates of $12.98 million. Intellia Therapeutics had a negative net margin of 672.16% and a negative return on equity of 57.79%. The firm's revenue for the quarter was down 46.4% on a year-over-year basis. During the same quarter last year, the business posted ($0.98) EPS. As a group, equities research analysts predict that Intellia Therapeutics will post -3.21 EPS for the current fiscal year. Insider activity. In other news, EVP Edward J. Dulac III sold 4,677 shares of the company's stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $18.00, for a total value of $84,186.00. Following the sale, the executive vice president owned 156,286 shares in the company, valued at $2,813,148. This represents a 2.91% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Michael P. Dube sold 2,641 shares of the firm's stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $16.78, for a total value of $44,315.98. Following the sale, the chief accounting officer owned 66,886 shares in the company, valued at $1,122,347.08. This trade represents a 3.80% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 3.50% of the stock is currently owned by insiders. Hedge funds weigh in on Intellia Therapeutics. Several hedge funds and other institutional investors have recently made changes to their positions in NTLA. BlackRock Inc. acquired a new stake in Intellia Therapeutics during the 2nd quarter worth $260,721,000. ARK Investment Management LLC lifted its holdings in Intellia Therapeutics by 19.2% in the fourth quarter. ARK Investment Management LLC now owns 14,207,324 shares of the company's stock valued at $127,724,000 after acquiring an additional 2,288,146 shares during the last quarter. Vanguard Group Inc. grew its position in Intellia Therapeutics by 17.8% in the fourth quarter. Vanguard Group Inc. now owns 13,010,001 shares of the company's stock worth $116,960,000 after acquiring an additional 1,965,181 shares during the period. State Street Corp raised its position in Intellia Therapeutics by 29.1% in the fourth quarter. State Street Corp now owns 6,418,836 shares of the company's stock valued at $57,705,000 after purchasing an additional 1,447,967 shares during the period. Finally, Geode Capital Management LLC grew its holdings in shares of Intellia Therapeutics by 4.1% during the 4th quarter. Geode Capital Management LLC now owns 2,696,187 shares of the company's stock worth $24,243,000 after purchasing an additional 107,333 shares during the period. Hedge funds and other institutional investors own 88.77% of the company's stock. Intellia Therapeutics news roundup. Here are the key news stories impacting Intellia Therapeutics this week: * The FDA granted Priority Review to Intellia's biologics license application for lonvo-z and set a PDUFA decision date of March 10, 2027. If approved, lonvo-z could become the first in vivo CRISPR-based therapy and the only one-time treatment for HAE, offering substantial commercial differentiation. * HC Wainwright reaffirmed its Buy rating and assigned a $25 price target, implying substantial potential upside from the stock's recent $12.74 level. The target reflects optimism about lonvo-z and Intellia's CRISPR platform. * Wedbush raised its price target to $13 from $12 but maintained a Neutral rating. The revised target indicates only limited near-term valuation upside and shows that analysts remain cautious despite the FDA milestone. * Intellia was highlighted among genomics companies attracting investor interest in 2026, reinforcing broader enthusiasm for gene-editing and precision-medicine technologies, but the article did not announce a new company-specific development. About Intellia Therapeutics. Intellia Therapeutics, Inc NASDAQ: NTLA is a clinical-stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company's research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease-causing genes with a single administration. Intellia's lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders. Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Intellia Therapeutics, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intellia Therapeutics wasn't on the list. While Intellia Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. Enter your email address and we'll send you MarketBeat's list of ten stocks set to soar in Fall 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Continue following MarketBeat